Key terms
About IFRX
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest IFRX news
Apr 04
4:58pm ET
InflaRx N.V. Announces 2024 AGM Details
Mar 24
9:25pm ET
Investor Optimism for InflaRx’s INF904: Assessing Potential in CSU and HS Markets
Mar 22
3:05pm ET
LifeSci Capital Reaffirms Their Hold Rating on InflaRx (IFRX)
Mar 22
6:16am ET
Buy Rating Justified for InflaRx Despite Earnings Miss: Financial Stability and INF904’s Market Potential
Mar 21
9:27pm ET
InflaRx Advances Anti-Inflammatory Therapeutics
Mar 21
7:57am ET
InflaRx N.V. Targets Immuno-Dermatology Growth
Mar 21
7:08am ET
InflaRx announces INF904 development plans
Mar 21
7:06am ET
InflaRx sees cash runway into at least 2026
Mar 21
7:05am ET
InflaRx reports 2023 EPS (EUR 0.78) vs. (EUR 0.67) last year
Feb 22
7:46am ET
InflaRx appoints Medina as Head of Investor Relations
Jan 25
11:25am ET
Buy Recommendation for InflaRx Amidst Strategic Initiatives and Promising Clinical Advances
Jan 25
11:14am ET
InflaRx price target lowered to $8 from $9 at H.C. Wainwright
Jan 25
7:32am ET
InflaRx announces initiation of its commitment program for GOHIBIC
Jan 09
1:30am ET
Analysts Offer Insights on Healthcare Companies: Walgreens Boots Alliance (WBA), InflaRx (IFRX) and Eli Lilly & Co (LLY)
Jan 05
6:28am ET
InflaRx’s Promising INF904 Phase 1 Results Prompt Buy Rating
No recent press releases are available for IFRX
IFRX Financials
Key terms
Ad Feedback
IFRX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
IFRX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range